DelveInsight’s “Generalized Anxiety Disorder Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Generalized Anxiety Disorder market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Generalized Anxiety Disorder drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Generalized Anxiety Disorder treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Generalized Anxiety Disorder: An Overview
Generalized anxiety disorder (GAD) is recognized as the most common anxiety disorder within primary care, carrying a significant degree of comorbidity, impairment, and disability. Generalized Anxiety Disorder is characterized by a chronic, persistent pattern of worrying, anxiety symptoms, and tension that has a waxing and waning course, often without full remission.
Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria is the updated criteria for Generalized Anxiety Disorder that separate out different mental disorders such as anxiety, selective mutism, specific phobia, social anxiety disorder (also called social phobia), panic disorder, agoraphobia, generalized anxiety, substance abuse/medication-induced anxiety, and other conditions caused by anxiety disorders
The criteria of Generalized Anxiety Disorder in DSM-V include characteristics, such as feeling restless, keyed up, or on edge, fatiguing easily, difficulty concentrating or the mind going blank, irritability, increased muscle tension, difficulty falling asleep, staying asleep, or restlessness. Excessive worry and anxiety occur most of the time for at least 6 months, with at least three of the core symptoms in adults and one sign in the case of children.
Generalized Anxiety Disorder often occurs along with other mental health problems, which can make diagnosis and treatment more challenging. Some mental health disorders that commonly occur with Generalized Anxiety Disorder are phobias, panic disorder, post-traumatic stress disorder (PTSD), obsessive-compulsive disorders, and others.
Generalized Anxiety Disorder Market Key Facts
The total 12-month prevalent patient population of Generalized Anxiety Disorder in the 7MM countries was close to 16 million cases in 2021.
According to DelveInsight estimates, among the EU-4 countries, Germany had the highest prevalence with an estimated 1,450,264 cases of Generalized Anxiety Disorder in 2022 and these cases are further expected to rise by 2032.
In 2022, in Germany, there were 491,000+ cases of Generalized Anxiety Disorder in males and 958,000+ cases in females. Assessments as per DelveInsight’s analysts show that the overall prevalence in both genders is subject to increase in the coming years.
According to the Anxiety and Depression Association of America (ADAA), in any given year, Generalized Anxiety Disorder affects 6.8 million adults or 3.1% of the US population. Women are twice as likely to be affected. Although the exact cause of Generalized Anxiety Disorder is unknown, there is evidence that biological factors, family background, and life experiences, particularly stressful ones, play a role.
Some of the key companies in the Generalized Anxiety Disorder Market include MindMed, VistaGen Therapeutics, Actavis, Takeda Pharmaceuticals, Bionomics, and others.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Generalized Anxiety Disorder pipeline therapies. It also thoroughly assesses the Generalized Anxiety Disorder market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Generalized Anxiety Disorder drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Generalized Anxiety Disorder Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Generalized Anxiety Disorder epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Generalized Anxiety Disorder epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Generalized Anxiety Disorder Epidemiology, Segmented as –
12-month prevalent cases of generalized anxiety disorder
Gender-specific cases of generalized anxiety disorder
Severity-specific cases of generalized anxiety disorder
Age-specific cases of generalized anxiety disorder
Generalized Anxiety Disorder Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Generalized Anxiety Disorder market or expected to be launched during the study period. The analysis covers the Generalized Anxiety Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Generalized Anxiety Disorder drugs based on their sale and market share.
The report also covers the Generalized Anxiety Disorder pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Generalized Anxiety Disorder companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Generalized Anxiety Disorder Market Will Evolve and Grow by 2032 @
Generalized Anxiety Disorder Therapeutics Analysis
Treatments for anxiety disorders might include psychological interventions, pharmacological interventions, or a combination of these modalities. Numerous psychotherapeutic methodologies have been used for Generalized Anxiety Disorder, including CBT, psychodynamic psychotherapy, and applied relaxation. Of these, CBT has the most evidence-based support and is the most common modality used today.
The standard category of pharmacological agents used in the management of Generalized Anxiety Disorder includes Selective serotonin reuptake inhibitors (SSRIs), Selective norepinephrine reuptake inhibitors (SNRIs), Pregabalin, Tricyclic antidepressants (TCAs), Benzodiazepines, Antihistamines, Atypical antipsychotics, Antioxidants, and others. Despite the availability of these therapies, there is a lack of efficient therapeutic agents as the available therapies have safety issues over older medication classes, though, they may have a slow onset of action, and patients may experience a troublesome side effect. Therefore, there is a high unmet need for developing safe and effective therapies.
Several major pharma and biotech companies are developing therapies for Generalized Anxiety Disorder. Currently, Mind Medicine is leading the therapeutics market with its Generalized Anxiety Disorder drug candidates in the mid to advanced stage of clinical development.
Generalized Anxiety Disorder Companies Actively Working in the Therapeutics Market Include
Mind Medicine, Inc.
And Many Others
Emerging and Marketed Generalized Anxiety Disorder Therapies Covered in the Report Include:
MM-120 (LSD D-Tartrate): Mind Medicine, Inc.
ENX-102: Engrail Therapeutics
PH49B: VistaGen’s Therapeutics
EXXUA: Fabre-Kramer Pharmaceuticals
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Generalized Anxiety Disorder Competitive Intelligence Analysis
4. Generalized Anxiety Disorder Market Overview at a Glance
5. Generalized Anxiety Disorder Disease Background and Overview
6. Generalized Anxiety Disorder Patient Journey
7. Generalized Anxiety Disorder Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Generalized Anxiety Disorder Treatment Algorithm, Current Treatment, and Medical Practices
9. Generalized Anxiety Disorder Unmet Needs
10. Key Endpoints of Generalized Anxiety Disorder Treatment
11. Generalized Anxiety Disorder Marketed Therapies
12. Generalized Anxiety Disorder Emerging Drugs and Latest Therapeutic Advances
13. Generalized Anxiety Disorder Seven Major Market Analysis
14. Attribute Analysis
15. Generalized Anxiety Disorder Market Outlook (In US, EU5, and Japan)
16. Generalized Anxiety Disorder Companies Active in the Market
17. Generalized Anxiety Disorder Access and Reimbursement Overview
18. KOL Views on the Generalized Anxiety Disorder Market
19. Generalized Anxiety Disorder Market Drivers
20. Generalized Anxiety Disorder Market Barriers
22. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Osteochondrodysplasia Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Osteochondrodysplasia market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Osteochondrodysplasia market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States